LifeSensors Attending the 5th Annual Targeted Protein Degradation Summit
MALVERN, PA., AUG 30, 2022 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, Molecular Glues, and neurodegeneration diagnostics has been invited to speak at 5th Targeted Protein Degradation Summit in Boston MA. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting at TPD conference in Boston. Current methods for discovering novel ligands for targeted protein ubiquitination are inefficient, cumbersome, or prone to artifacts. Dr. Kadimisetty will discuss a LifeSensors platform that directly measures PROTAC or molecular glue mediated ubiquitination of the targets.
For the first time LifeSensors will disclose novel technologies to discover unique PROTAC and molecular glues whose mechanisms have the potential to deliver breakthrough drugs. Both challenges and new developments in the field of ligand mediated ubiquitination will be discussed.
LifeSensors. Inc. partners with pharma and biotech companies and helps life scientists innovate in basic research, drug discovery and diagnostics. We pioneered the SUMO-fusion system for high quality protein expression. Our development of cutting-edge tools for the ubiquitin proteasome system (UPS) and Protein Targeting Chimers (PROTAC) allow scientists new ways to observe and discover the fundamentals of this emerging area in medicine. Poly-ubiquitin affinity matrices, Tandem Ubiquitin Binding Entities (TUBES), are changing the way scientists make discoveries in UPS and identify novel biomarkers for neurodegeneration and drug discovery. We are making an impact in the lives of scientists through innovation and pushing the envelope with regards to novel research techniques not only in PROTACs but in the growing and highly applicable areas of Molecular Glues and other technology regarding the ubiquitin proteasome system.
Contact: Isabelle Wentzel
(610) 644-8845 EXT. 304